Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Ardelyx (ARDX) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's Chief Financial and Operations Officer, Justin Renz, and Chief Commercial Officer, Eric Foster, will engage in a fireside chat on Wednesday, December 4, 2024, at 12:30pm EST in New York City.
The presentation will be accessible via live webcast on the Events and Presentations page of Ardelyx's website, with a replay available for 30 days following the event.
Ardelyx (ARDX) ha annunciato la sua partecipazione alla 36° Conferenza Annuale sulla Salute di Piper Sandler. Il Direttore Finanziario e Operativo della compagnia, Justin Renz, e il Direttore Commerciale, Eric Foster, parteciperanno a una chiacchierata informale mercoledì 4 dicembre 2024, alle 12:30 EST a New York.
La presentazione sarà accessibile tramite una trasmissione in diretta sulla pagina Eventi e Presentazioni del sito web di Ardelyx, con una registrazione disponibile per 30 giorni dopo l'evento.
Ardelyx (ARDX) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El Director Financiero y de Operaciones de la compañía, Justin Renz, y el Director Comercial, Eric Foster, participarán en una conversación informal el miércoles 4 de diciembre de 2024, a las 12:30 p.m. EST en Nueva York.
La presentación estará disponible a través de una transmisión en vivo en la página de Eventos y Presentaciones del sitio web de Ardelyx, con una repetición disponible durante 30 días después del evento.
Ardelyx (ARDX)는 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여할 것임을 발표했습니다. 회사의 최고 재무 및 운영 책임자인 Justin Renz와 최고 상업 책임자인 Eric Foster는 2024년 12월 4일 수요일 오후 12시 30분 EST에 뉴욕에서 fireside chat에 참여할 예정입니다.
프레젠테이션은 Ardelyx 웹사이트의 이벤트 및 프레젠테이션 페이지를 통해 라이브 웹캐스트로 접근할 수 있으며, 이벤트 후 30일 동안 재생할 수 있는 녹화도 제공됩니다.
Ardelyx (ARDX) a annoncé sa participation à la 36e Conférence Annuelle de Santé de Piper Sandler. Le Directeur Financier et des Opérations de l'entreprise, Justin Renz, et le Directeur Commercial, Eric Foster, participeront à une discussion informelle le mercredi 4 décembre 2024, à 12h30 EST à New York.
La présentation sera accessible par le biais d'une diffusion en direct sur la page Événements et Présentations du site web d'Ardelyx, avec une rediffusion disponible pendant 30 jours après l'événement.
Ardelyx (ARDX) hat seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler angekündigt. Der Chief Financial and Operations Officer des Unternehmens, Justin Renz, und der Chief Commercial Officer, Eric Foster, werden am Mittwoch, den 4. Dezember 2024, um 12:30 Uhr EST in New York City an einem Fireside-Chat teilnehmen.
Die Präsentation wird über einen Live-Webcast auf der Seite für Veranstaltungen und Präsentationen der Ardelyx-Website zugänglich sein, mit einer Aufzeichnung, die 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New York City.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When is Ardelyx (ARDX) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Ardelyx's (ARDX) presentation at the Piper Sandler Conference?
How long will Ardelyx's (ARDX) Piper Sandler Conference presentation be available for replay?
Which Ardelyx (ARDX) executives are participating in the Piper Sandler Healthcare Conference?
